<p>深圳，2026 年 4 月 23 日 -（ACN Newswire）- 中國醫療系統控股有限公司（&#34;集團&#34;或&#34;CMS&#34;）欣然宣佈，針對 MG-K10（通用名：Comekibart 注射液，&#34;MG-K10&#34;或&#34;產品&#34;）的季節性過敏性鼻炎（SAR）適應症的中國新藥申請（NDA）已於 2026 年 4 月 23 日獲得中國國家藥品監督管理局（NMPA）的受理。該產品是一種 1 類創新藥物，抗 IL-4Ra 人源化單克隆抗體注射劑，集團擁有共同開發權（不包括特應性皮炎（AD）適應症）和獨佔商業化權利。該產品旨在治療中度至重度季節性過敏性鼻炎的成年患者，這些患者在使用鼻用皮質類固醇治療後症狀仍未得到有效控制。</p>
<p>NDA 的受理標誌着集團眼科業務 CMS Vision 的重要里程碑，因為它將治療重點從眼科擴展到耳鼻喉科（ENT）領域。這也標誌着集團在 2 型炎症性疾病研究與開發進展中的另一個重要里程碑。如果該產品成功獲得市場批准，集團將利用其強大的學術推廣能力和廣泛的商業化網絡，加速該產品的商業化。預計這還將進一步增強 CMS Vision 在相關專業領域的學術品牌影響力，併為集團的業務增長提供新的動力。</p>
<p>BIC 潛力：每 4 周給藥一次；III 期研究達到了主要終點，安全性良好</p>
<p>MG-K10 是一種創新的長效抗 IL-4Ra 人源化單克隆抗體，能夠同時阻斷關鍵的 2 型炎症細胞因子 IL-4 和 IL-13 的信號通路，從而發揮免疫調節作用。該藥物正在開發用於治療 2 型炎症性疾病，包括季節性過敏性鼻炎、哮喘、特應性皮炎（AD）、結節性瘙癢、慢性阻塞性肺病（COPD）、慢性自發性蕁麻疹（CSU）、伴鼻息肉的慢性鼻竇炎和嗜酸性食管炎。目前市場上的抗 IL-4Ra 療法需要每兩週給藥一次。MG-K10 具有更長的半衰期，能夠實現每 4 周給藥一次。因此，它有潛力成為全球首個上市的長效抗 IL-4Ra 單克隆抗體，可能成為同類最佳。MG-K10 在一項針對中度至重度季節性過敏性鼻炎成年患者的多中心、隨機、雙盲、安慰劑對照的 III 期臨牀試驗中達到了主要終點。III 期研究的結果表明，主要終點達到了統計學顯著性，與安慰劑組相比，療效顯著優越，且安全性良好。</p>
<p>關注未滿足的需求：約 2.5 億患者；62% 的中度至重度患者未得到有效控制；長效突破帶來新的治療機會</p>
<p>過敏性鼻炎是一種由 IgE 介導的鼻粘膜慢性炎症性疾病，其核心致病機制為 2 型炎症。它在易感個體中因接觸花粉和塵蟎等環境過敏原而發生。近年來，中國該疾病的患病率從 11.1% 上升至 17.6%，影響約 2.5 億人 [1]，其中 52.2% 為持續性中度至重度患者 [2]。該疾病負擔顯著，已成為一個重要的公共衞生問題。目前的標準治療，包括鼻用皮質類固醇和抗組胺藥，存在明顯的侷限性。62% 的中度至重度患者未得到有效控制 [3]。長期使用鼻用皮質類固醇可能導致不良反應，如鼻出血 [4]，而抗組胺藥常常伴隨嗜睡等副作用 [5]，這表明臨牀需求顯著未得到滿足。作為一種針對 IL-4Ra 的生物治療，MG-K10 可以從源頭阻斷 2 型炎症通路。與目前批准的針對同一通路的生物製劑（需要每兩週給藥一次）相比，MG-K10 在給藥頻率上實現了差異化突破，其長效特性允許每 4 周給藥一次，從而顯著延長了給藥間隔。這可能有助於改善患者的治療依從性，減少頻繁就醫所帶來的時間和經濟負擔。該產品有潛力為對常規療法反應不佳的中度至重度患者提供新的治療選擇，從而減輕與該疾病相關的個人和社會經濟負擔。</p>
<p>2025 年 1 月 24 日，集團通過其子公司與湖南瑪貝克生物科技有限公司及其子公司簽署了合作協議（&#34;協議&#34;），涉及 MG-K10。根據協議及補充協議，集團已獲得該產品在中國大陸、香港特別行政區、澳門特別行政區、台灣地區和新加坡的共同開發權（不包括 AD）和獨佔商業化權利；其子公司 Dermavon Holdings Limited 通過其子公司獲得了該產品在中國大陸皮膚科適應症領域的共同開發權（不包括 AD）和獨佔商業化權利。</p>
<p>關於 CMS</p>
<p>CMS 是一家將製藥創新與商業化相結合的平台公司，具備強大的產品生命週期管理能力，致力於提供具有競爭力的產品和服務，以滿足未滿足的醫療需求。</p>
<p>CMS 專注於全球首創（FIC）和最佳（BIC）創新產品，高效推動創新產品的臨牀研究、開發和商業化，實現科學研究向臨牀實踐的持續轉化，以造福患者。</p>
<p>CMS 深入參與多個專業治療領域，已建立了成熟的商業化能力、廣泛的網絡和專家資源，使其主要上市產品在學術和市場上佔據領先地位。CMS 持續推動其優勢專業領域的深入發展，增強心血管 - 腎臟 - 代謝/胃腸病/眼科/皮膚健康業務的競爭力，帶來專業領域的規模經濟。其中，皮膚健康業務（Dermavon）已成為該領域的領先企業，並計劃在香港聯合交易所獨立上市。同時，CMS 持續推動其在東南亞和中東的綜合研發、製造和商業化鏈的運營與發展，把握新興市場的增長機會，支持集團的高質量和可持續發展。</p>
<p>參考文獻</p>
<p>1. Cheng L, Chen J, Fu Q, 等. 中國過敏學會過敏性鼻炎診斷與治療指南. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
<p>2. Zheng, Ming 等. &#34;中國 13 個大城市過敏性鼻炎患者的臨牀特徵.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
<p>3. White, P 等. &#34;英國普通實踐中花粉症患者的症狀控制：我們做得怎麼樣，是否需要過敏原免疫治療？&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
<p>4. Rosenblut, A 等. &#34;氟替卡松呋喃鼻噴霧劑在成人和青少年中的長期安全性研究。&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
<p>5. Bernstein, Jonathan A 等. &#34;過敏性鼻炎：綜述。&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
<p>CMS 免責聲明及前瞻性聲明</p>
<p>本新聞稿並不旨在向您推廣任何產品，也不用於廣告目的。本新聞稿不推薦任何藥物、醫療器械和/或適應症。如果您想了解特定疾病的診斷和治療，請遵循您的醫生或其他醫療健康專業人士的意見或指導。醫療專業人士所做的任何治療相關決策應基於患者的具體情況，並符合藥品説明書。</p>
<p>本新聞稿由 CMS 準備，並不構成任何購買或認購任何證券的要約或邀請，也不應作為任何合同或具有約束力的承諾的基礎或依賴。此新聞稿是基於 CMS 認為可靠的信息和數據準備的，但 CMS 不作任何明示或暗示的陳述或保證，且不應依賴於本新聞稿內容的真實性、準確性、完整性、公平性和合理性。此新聞稿中討論的某些事項可能包含關於集團市場機會和商業前景的聲明，這些聲明單獨或共同構成前瞻性聲明。此類前瞻性聲明並不保證未來的表現，並且受到已知和未知的風險、不確定性和假設的影響，這些因素難以預測。此新聞稿中包含的第三方所作的任何前瞻性聲明和預測不被集團採納，且公司對這些第三方聲明和預測不承擔責任。</p>
<p>媒體聯繫</p>
<p>品牌：中國醫療系統控股有限公司。</p>
<p>聯繫人：CMS 投資者關係</p>
<p>電子郵件：ir@cms.net.cn</p>
<p>網站：https://web.cms.net.cn/en/home/</p>
<p>來源：中國醫療系統控股有限公司</p>
<p>版權 © 2026 ACN Newswire . 保留所有權利。</p>

<p>中國醫療系統控股有限公司（CMS）宣佈，其創新藥物 MG-K10 的新藥申請（NDA）已被中國國家藥品監督管理局接受。該藥物也被稱為 Comekibart 注射液，旨在治療中度至重度的季節性過敏性鼻炎（SAR），適用於使用鼻用皮質類固醇治療效果不佳的成年人。CMS 擁有 MG-K10 的獨家商業化權利，但不包括其在特應性皮炎中的使用</p>

<p>SHENZHEN, Apr 23, 2026 - (ACN Newswire) - China Medical System Holdings Limited (the &#34;Group&#34; or &#34;CMS&#34;) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, &#34;MG-K10&#34; or the &#34;Product&#34;), a Class 1 innovative drug anti-IL-4Ra humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.</p>
<div class="lb-trans"><p>深圳，2026 年 4 月 23 日 -（ACN Newswire）- 中國醫療系統控股有限公司（&#34;集團&#34;或&#34;CMS&#34;）欣然宣佈，針對 MG-K10（通用名：Comekibart 注射液，&#34;MG-K10&#34;或&#34;產品&#34;）的季節性過敏性鼻炎（SAR）適應症的中國新藥申請（NDA）已於 2026 年 4 月 23 日獲得中國國家藥品監督管理局（NMPA）的受理。該產品是一種 1 類創新藥物，抗 IL-4Ra 人源化單克隆抗體注射劑，集團擁有共同開發權（不包括特應性皮炎（AD）適應症）和獨佔商業化權利。該產品旨在治療中度至重度季節性過敏性鼻炎的成年患者，這些患者在使用鼻用皮質類固醇治療後症狀仍未得到有效控制。</p>
</div><p>The acceptance of the NDA represents an important milestone for the Group's ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group's research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group's business growth.</p>
<div class="lb-trans"><p>NDA 的受理標誌着集團眼科業務 CMS Vision 的重要里程碑，因為它將治療重點從眼科擴展到耳鼻喉科（ENT）領域。這也標誌着集團在 2 型炎症性疾病研究與開發進展中的另一個重要里程碑。如果該產品成功獲得市場批准，集團將利用其強大的學術推廣能力和廣泛的商業化網絡，加速該產品的商業化。預計這還將進一步增強 CMS Vision 在相關專業領域的學術品牌影響力，併為集團的業務增長提供新的動力。</p>
</div><p>BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profile</p>
<div class="lb-trans"><p>BIC 潛力：每 4 周給藥一次；III 期研究達到了主要終點，安全性良好</p>
</div><p>MG-K10 is an innovative long-acting anti-IL-4Ra humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Ra therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Ra monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.</p>
<div class="lb-trans"><p>MG-K10 是一種創新的長效抗 IL-4Ra 人源化單克隆抗體，能夠同時阻斷關鍵的 2 型炎症細胞因子 IL-4 和 IL-13 的信號通路，從而發揮免疫調節作用。該藥物正在開發用於治療 2 型炎症性疾病，包括季節性過敏性鼻炎、哮喘、特應性皮炎（AD）、結節性瘙癢、慢性阻塞性肺病（COPD）、慢性自發性蕁麻疹（CSU）、伴鼻息肉的慢性鼻竇炎和嗜酸性食管炎。目前市場上的抗 IL-4Ra 療法需要每兩週給藥一次。MG-K10 具有更長的半衰期，能夠實現每 4 周給藥一次。因此，它有潛力成為全球首個上市的長效抗 IL-4Ra 單克隆抗體，可能成為同類最佳。MG-K10 在一項針對中度至重度季節性過敏性鼻炎成年患者的多中心、隨機、雙盲、安慰劑對照的 III 期臨牀試驗中達到了主要終點。III 期研究的結果表明，主要終點達到了統計學顯著性，與安慰劑組相比，療效顯著優越，且安全性良好。</p>
</div><p>Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunities</p>
<div class="lb-trans"><p>關注未滿足的需求：約 2.5 億患者；62% 的中度至重度患者未得到有效控制；長效突破帶來新的治療機會</p>
</div><p>Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Ra, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.</p>
<div class="lb-trans"><p>過敏性鼻炎是一種由 IgE 介導的鼻粘膜慢性炎症性疾病，其核心致病機制為 2 型炎症。它在易感個體中因接觸花粉和塵蟎等環境過敏原而發生。近年來，中國該疾病的患病率從 11.1% 上升至 17.6%，影響約 2.5 億人 [1]，其中 52.2% 為持續性中度至重度患者 [2]。該疾病負擔顯著，已成為一個重要的公共衞生問題。目前的標準治療，包括鼻用皮質類固醇和抗組胺藥，存在明顯的侷限性。62% 的中度至重度患者未得到有效控制 [3]。長期使用鼻用皮質類固醇可能導致不良反應，如鼻出血 [4]，而抗組胺藥常常伴隨嗜睡等副作用 [5]，這表明臨牀需求顯著未得到滿足。作為一種針對 IL-4Ra 的生物治療，MG-K10 可以從源頭阻斷 2 型炎症通路。與目前批准的針對同一通路的生物製劑（需要每兩週給藥一次）相比，MG-K10 在給藥頻率上實現了差異化突破，其長效特性允許每 4 周給藥一次，從而顯著延長了給藥間隔。這可能有助於改善患者的治療依從性，減少頻繁就醫所帶來的時間和經濟負擔。該產品有潛力為對常規療法反應不佳的中度至重度患者提供新的治療選擇，從而減輕與該疾病相關的個人和社會經濟負擔。</p>
</div><p>On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (&#34;Agreement&#34;) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.</p>
<div class="lb-trans"><p>2025 年 1 月 24 日，集團通過其子公司與湖南瑪貝克生物科技有限公司及其子公司簽署了合作協議（&#34;協議&#34;），涉及 MG-K10。根據協議及補充協議，集團已獲得該產品在中國大陸、香港特別行政區、澳門特別行政區、台灣地區和新加坡的共同開發權（不包括 AD）和獨佔商業化權利；其子公司 Dermavon Holdings Limited 通過其子公司獲得了該產品在中國大陸皮膚科適應症領域的共同開發權（不包括 AD）和獨佔商業化權利。</p>
</div><p>About CMS</p>
<div class="lb-trans"><p>關於 CMS</p>
</div><p>CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.</p>
<div class="lb-trans"><p>CMS 是一家將製藥創新與商業化相結合的平台公司，具備強大的產品生命週期管理能力，致力於提供具有競爭力的產品和服務，以滿足未滿足的醫療需求。</p>
</div><p>CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.</p>
<div class="lb-trans"><p>CMS 專注於全球首創（FIC）和最佳（BIC）創新產品，高效推動創新產品的臨牀研究、開發和商業化，實現科學研究向臨牀實踐的持續轉化，以造福患者。</p>
</div><p>CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&amp;D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.</p>
<div class="lb-trans"><p>CMS 深入參與多個專業治療領域，已建立了成熟的商業化能力、廣泛的網絡和專家資源，使其主要上市產品在學術和市場上佔據領先地位。CMS 持續推動其優勢專業領域的深入發展，增強心血管 - 腎臟 - 代謝/胃腸病/眼科/皮膚健康業務的競爭力，帶來專業領域的規模經濟。其中，皮膚健康業務（Dermavon）已成為該領域的領先企業，並計劃在香港聯合交易所獨立上市。同時，CMS 持續推動其在東南亞和中東的綜合研發、製造和商業化鏈的運營與發展，把握新興市場的增長機會，支持集團的高質量和可持續發展。</p>
</div><p>Reference</p>
<div class="lb-trans"><p>參考文獻</p>
</div><p>1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
<div class="lb-trans"><p>1. Cheng L, Chen J, Fu Q, 等. 中國過敏學會過敏性鼻炎診斷與治療指南. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
</div><p>2. Zheng, Ming et al. &#34;Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
<div class="lb-trans"><p>2. Zheng, Ming 等. &#34;中國 13 個大城市過敏性鼻炎患者的臨牀特徵.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
</div><p>3. White, P et al. &#34;Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
<div class="lb-trans"><p>3. White, P 等. &#34;英國普通實踐中花粉症患者的症狀控制：我們做得怎麼樣，是否需要過敏原免疫治療？&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
</div><p>4. Rosenblut, A et al. &#34;Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
<div class="lb-trans"><p>4. Rosenblut, A 等. &#34;氟替卡松呋喃鼻噴霧劑在成人和青少年中的長期安全性研究。&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
</div><p>5. Bernstein, Jonathan A et al. &#34;Allergic Rhinitis: A Review.&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
<div class="lb-trans"><p>5. Bernstein, Jonathan A 等. &#34;過敏性鼻炎：綜述。&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
</div><p>CMS Disclaimer and Forward-Looking Statements</p>
<div class="lb-trans"><p>CMS 免責聲明及前瞻性聲明</p>
</div><p>This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug package insert.</p>
<div class="lb-trans"><p>本新聞稿並不旨在向您推廣任何產品，也不用於廣告目的。本新聞稿不推薦任何藥物、醫療器械和/或適應症。如果您想了解特定疾病的診斷和治療，請遵循您的醫生或其他醫療健康專業人士的意見或指導。醫療專業人士所做的任何治療相關決策應基於患者的具體情況，並符合藥品説明書。</p>
</div><p>This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.</p>
<div class="lb-trans"><p>本新聞稿由 CMS 準備，並不構成任何購買或認購任何證券的要約或邀請，也不應作為任何合同或具有約束力的承諾的基礎或依賴。此新聞稿是基於 CMS 認為可靠的信息和數據準備的，但 CMS 不作任何明示或暗示的陳述或保證，且不應依賴於本新聞稿內容的真實性、準確性、完整性、公平性和合理性。此新聞稿中討論的某些事項可能包含關於集團市場機會和商業前景的聲明，這些聲明單獨或共同構成前瞻性聲明。此類前瞻性聲明並不保證未來的表現，並且受到已知和未知的風險、不確定性和假設的影響，這些因素難以預測。此新聞稿中包含的第三方所作的任何前瞻性聲明和預測不被集團採納，且公司對這些第三方聲明和預測不承擔責任。</p>
</div><p>Media Contact</p>
<div class="lb-trans"><p>媒體聯繫</p>
</div><p>Brand: China Medical System Holdings Ltd.</p>
<div class="lb-trans"><p>品牌：中國醫療系統控股有限公司。</p>
</div><p>Contact: CMS Investor Relations</p>
<div class="lb-trans"><p>聯繫人：CMS 投資者關係</p>
</div><p>Email: ir@cms.net.cn</p>
<div class="lb-trans"><p>電子郵件：ir@cms.net.cn</p>
</div><p>Website: https://web.cms.net.cn/en/home/</p>
<div class="lb-trans"><p>網站：https://web.cms.net.cn/en/home/</p>
</div><p>Source: China Medical System Holdings Limited</p>
<div class="lb-trans"><p>來源：中國醫療系統控股有限公司</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版權 © 2026 ACN Newswire . 保留所有權利。</p>
</div>

CMS; 8A8.SG): 1 類創新藥 MG-K10 用於季節性過敏性鼻炎的上市申請在中國已被受理